Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Deferred Taxes (2024 - 2025)

Historic Deferred Taxes for Cytek Biosciences (CTKB) over the last 2 years, with Q3 2025 value amounting to -$2.6 million.

  • Cytek Biosciences' Deferred Taxes changed N/A to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.9 million, marking a year-over-year change of. This contributed to the annual value of -$2.9 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Cytek Biosciences reported Deferred Taxes of -$2.6 million as of Q3 2025.
  • Cytek Biosciences' Deferred Taxes' 5-year high stood at -$336000.0 during Q1 2025, with a 5-year trough of -$2.9 million in Q4 2024.